Clinical Trials Logo

Adenoid Cystic Carcinoma clinical trials

View clinical trials related to Adenoid Cystic Carcinoma.

Filter by:

NCT ID: NCT03556228 Recruiting - Breast Cancer Clinical Trials

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Start date: June 8, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

NCT ID: NCT02942693 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Start date: November 2016
Phase: Phase 2
Study type: Interventional

It is a randomized phase II study to determine the efficacy and safety of particle therapy with or without apatinib as induction therapy for the treatment of head and neck adenoid cystic carcinoma. Participants will be randomized to arm 1: receiving apatinib for 6 weekly followed by particle radiotherapy; arm 2: particle radiotherapy alone.

NCT ID: NCT01192087 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy

ACCEPT
Start date: June 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The ACCEPT (A(denoid) c(ystic) c(arcinoma), E(rbitux, and) p(article) t(herapy))-trial is a prospective, monocentric phase I/II feasibility trial evaluating toxicity and efficacy in the combined treatment of intensity-modulated radiation therapy (IMRT) and carbon ion (C12) boost with the epidermal growth factor receptor (EGFR) antibody cetuximab. The primary objective of the study is to explore the toxicity of the combined modality regimen consisting of heavy ion therapy / IMRT and EGFR antibody immunotherapy, by assessing the rate of patients with mucositis or any other toxicity of severity grade 3 or 4 according to NCI CTCAE V. 4. Secondary endpoints include local control, distant control, overall disease-free survival, overall survival